 | • レポートコード：MRC2012A7684 • 出版社/出版日：GlobalInfoResearch / 2020年12月24日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品、医療 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、肺動脈性肺高血圧症治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。肺動脈性肺高血圧症治療の種類別市場規模（血管拡張薬、ホスホジエステラーゼ5（PDE 5）阻害薬、エンドセリン受容体拮抗薬（ERA）、可溶性グアニル酸シクラーゼ（SGC）刺激薬）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：GlaxoSmithKline plc、Bayer AG、United Therapeutic Corporation、Eli Lilly and Company、Teva Pharmaceuticals Inc、Pfizer Inc.Actelion Inc、Gilead Sciences, Inc、SteadyMed Ltd、 ・地域別グローバル市場分析 2015年-2020年 ・肺動脈性肺高血圧症治療の北米市場（アメリカ、カナダ、メキシコ） ・肺動脈性肺高血圧症治療のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・肺動脈性肺高血圧症治療のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・肺動脈性肺高血圧症治療の南米市場（ブラジル、アルゼンチン） ・肺動脈性肺高血圧症治療の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：血管拡張薬、ホスホジエステラーゼ5（PDE 5）阻害薬、エンドセリン受容体拮抗薬（ERA）、可溶性グアニル酸シクラーゼ（SGC）刺激薬 ・用途別分析：病院薬局、小売薬局、オンライン薬局 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Pulmonary Arterial Hypertension Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 5.8% in the forecast period of 2020 to 2025 and will expected to reach USD 8665.6 million by 2025, from USD 6911.2 million in 2019.
The Pulmonary Arterial Hypertension Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Pulmonary Arterial Hypertension Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Pulmonary Arterial Hypertension Treatment market has been segmented into
Vasodilators
Phosphodiesterase 5 (PDE 5) Inhibitors
Endothelin Receptor Antagonists (ERA)
Soluble Guanylate Cyclase (SGC) Stimulator
By Application, Pulmonary Arterial Hypertension Treatment has been segmented into:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Pulmonary Arterial Hypertension Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Pulmonary Arterial Hypertension Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Pulmonary Arterial Hypertension Treatment market.
The report offers in-depth assessment of the growth and other aspects of the Pulmonary Arterial Hypertension Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Pulmonary Arterial Hypertension Treatment Market Share Analysis
Pulmonary Arterial Hypertension Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Pulmonary Arterial Hypertension Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Pulmonary Arterial Hypertension Treatment sales, revenue and market share for each player covered in this report.
The major players covered in Pulmonary Arterial Hypertension Treatment are:
GlaxoSmithKline plc
Bayer AG
United Therapeutic Corporation
Eli Lilly and Company
Teva Pharmaceuticals Inc
Pfizer Inc.Actelion Inc
Gilead Sciences, Inc
SteadyMed Ltd
Among other players domestic and global, Pulmonary Arterial Hypertension Treatment market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Pulmonary Arterial Hypertension Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Pulmonary Arterial Hypertension Treatment, with price, sales, revenue and global market share of Pulmonary Arterial Hypertension Treatment in 2018 and 2019.
Chapter 3, the Pulmonary Arterial Hypertension Treatment competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Pulmonary Arterial Hypertension Treatment breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Pulmonary Arterial Hypertension Treatment market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Pulmonary Arterial Hypertension Treatment sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Pulmonary Arterial Hypertension Treatment Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Pulmonary Arterial Hypertension Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Vasodilators
1.2.3 Phosphodiesterase 5 (PDE 5) Inhibitors
1.2.4 Endothelin Receptor Antagonists (ERA)
1.2.5 Soluble Guanylate Cyclase (SGC) Stimulator
1.3 Market Analysis by Application
1.3.1 Overview: Global Pulmonary Arterial Hypertension Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Overview of Global Pulmonary Arterial Hypertension Treatment Market
1.4.1 Global Pulmonary Arterial Hypertension Treatment Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 GlaxoSmithKline plc
2.1.1 GlaxoSmithKline plc Details
2.1.2 GlaxoSmithKline plc Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 GlaxoSmithKline plc SWOT Analysis
2.1.4 GlaxoSmithKline plc Product and Services
2.1.5 GlaxoSmithKline plc Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Bayer AG
2.2.1 Bayer AG Details
2.2.2 Bayer AG Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Bayer AG SWOT Analysis
2.2.4 Bayer AG Product and Services
2.2.5 Bayer AG Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 United Therapeutic Corporation
2.3.1 United Therapeutic Corporation Details
2.3.2 United Therapeutic Corporation Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 United Therapeutic Corporation SWOT Analysis
2.3.4 United Therapeutic Corporation Product and Services
2.3.5 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Eli Lilly and Company
2.4.1 Eli Lilly and Company Details
2.4.2 Eli Lilly and Company Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Eli Lilly and Company SWOT Analysis
2.4.4 Eli Lilly and Company Product and Services
2.4.5 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Teva Pharmaceuticals Inc
2.5.1 Teva Pharmaceuticals Inc Details
2.5.2 Teva Pharmaceuticals Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Teva Pharmaceuticals Inc SWOT Analysis
2.5.4 Teva Pharmaceuticals Inc Product and Services
2.5.5 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Pfizer Inc.Actelion Inc
2.6.1 Pfizer Inc.Actelion Inc Details
2.6.2 Pfizer Inc.Actelion Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Pfizer Inc.Actelion Inc SWOT Analysis
2.6.4 Pfizer Inc.Actelion Inc Product and Services
2.6.5 Pfizer Inc.Actelion Inc Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Gilead Sciences, Inc
2.7.1 Gilead Sciences, Inc Details
2.7.2 Gilead Sciences, Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Gilead Sciences, Inc SWOT Analysis
2.7.4 Gilead Sciences, Inc Product and Services
2.7.5 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.8 SteadyMed Ltd
2.8.1 SteadyMed Ltd Details
2.8.2 SteadyMed Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 SteadyMed Ltd SWOT Analysis
2.8.4 SteadyMed Ltd Product and Services
2.8.5 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Pulmonary Arterial Hypertension Treatment Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Pulmonary Arterial Hypertension Treatment Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Pulmonary Arterial Hypertension Treatment Manufacturer Market Share in 2019
3.3.2 Top 6 Pulmonary Arterial Hypertension Treatment Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Pulmonary Arterial Hypertension Treatment Sales, Revenue and Market Share by Regions
4.1.1 Global Pulmonary Arterial Hypertension Treatment Sales and Market Share by Regions (2015-2020)
4.1.2 Global Pulmonary Arterial Hypertension Treatment Revenue and Market Share by Regions (2015-2020)
4.2 North America Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
4.3 Europe Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
4.5 South America Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Pulmonary Arterial Hypertension Treatment Sales, Revenue and Market Share by Country
5.1.1 North America Pulmonary Arterial Hypertension Treatment Sales and Market Share by Country (2015-2020)
5.1.2 North America Pulmonary Arterial Hypertension Treatment Revenue and Market Share by Country (2015-2020)
5.2 United States Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
5.3 Canada Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
5.4 Mexico Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Pulmonary Arterial Hypertension Treatment Sales, Revenue and Market Share by Country
6.1.1 Europe Pulmonary Arterial Hypertension Treatment Sales and Market Share by Country (2015-2020)
6.1.2 Europe Pulmonary Arterial Hypertension Treatment Revenue and Market Share by Country (2015-2020)
6.2 Germany Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
6.3 UK Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
6.4 France Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
6.5 Russia Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
6.6 Italy Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Pulmonary Arterial Hypertension Treatment Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Pulmonary Arterial Hypertension Treatment Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Pulmonary Arterial Hypertension Treatment Revenue and Market Share by Regions (2015-2020)
7.2 China Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
7.3 Japan Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
7.4 Korea Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
7.5 India Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
7.7 Australia Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Pulmonary Arterial Hypertension Treatment Sales, Revenue and Market Share by Country
8.1.1 South America Pulmonary Arterial Hypertension Treatment Sales and Market Share by Country (2015-2020)
8.1.2 South America Pulmonary Arterial Hypertension Treatment Revenue and Market Share by Country (2015-2020)
8.2 Brazil Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
8.3 Argentina Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Pulmonary Arterial Hypertension Treatment Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Pulmonary Arterial Hypertension Treatment Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Pulmonary Arterial Hypertension Treatment Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
9.3 Turkey Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
9.4 Egypt Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
9.5 South Africa Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Pulmonary Arterial Hypertension Treatment Sales and Market Share by Type (2015-2020)
10.2 Global Pulmonary Arterial Hypertension Treatment Revenue and Market Share by Type (2015-2020)
10.3 Global Pulmonary Arterial Hypertension Treatment Price by Type (2015-2020)
11 Global Pulmonary Arterial Hypertension Treatment Market Segment by Application
11.1 Global Pulmonary Arterial Hypertension Treatment Sales Market Share by Application (2015-2020)
11.2 Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Application (2015-2020)
11.3 Global Pulmonary Arterial Hypertension Treatment Price by Application (2015-2020)
12 Market Forecast
12.1 Global Pulmonary Arterial Hypertension Treatment Sales, Revenue and Growth Rate (2021-2025)
12.2 Pulmonary Arterial Hypertension Treatment Market Forecast by Regions (2021-2025)
12.2.1 North America Pulmonary Arterial Hypertension Treatment Market Forecast (2021-2025)
12.2.2 Europe Pulmonary Arterial Hypertension Treatment Market Forecast (2021-2025)
12.2.3 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Forecast (2021-2025)
12.2.4 South America Pulmonary Arterial Hypertension Treatment Market Forecast (2021-2025)
12.2.5 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Forecast (2021-2025)
12.3 Pulmonary Arterial Hypertension Treatment Market Forecast by Type (2021-2025)
12.3.1 Global Pulmonary Arterial Hypertension Treatment Sales Forecast by Type (2021-2025)
12.3.2 Global Pulmonary Arterial Hypertension Treatment Market Share Forecast by Type (2021-2025)
12.4 Pulmonary Arterial Hypertension Treatment Market Forecast by Application (2021-2025)
12.4.1 Global Pulmonary Arterial Hypertension Treatment Sales Forecast by Application (2021-2025)
12.4.2 Global Pulmonary Arterial Hypertension Treatment Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Pulmonary Arterial Hypertension Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Pulmonary Arterial Hypertension Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Pulmonary Arterial Hypertension Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. GlaxoSmithKline plc Basic Information, Manufacturing Base and Competitors
Table 8. GlaxoSmithKline plc Pulmonary Arterial Hypertension Treatment Major Business
Table 9. GlaxoSmithKline plc Pulmonary Arterial Hypertension Treatment Total Revenue (USD Million) (2017-2018)
Table 10. GlaxoSmithKline plc SWOT Analysis
Table 11. GlaxoSmithKline plc Pulmonary Arterial Hypertension Treatment Product and Services
Table 12. GlaxoSmithKline plc Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Bayer AG Basic Information, Manufacturing Base and Competitors
Table 14. Bayer AG Pulmonary Arterial Hypertension Treatment Major Business
Table 15. Bayer AG Pulmonary Arterial Hypertension Treatment Total Revenue (USD Million) (2017-2018)
Table 16. Bayer AG SWOT Analysis
Table 17. Bayer AG Pulmonary Arterial Hypertension Treatment Product and Services
Table 18. Bayer AG Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. United Therapeutic Corporation Basic Information, Manufacturing Base and Competitors
Table 20. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Major Business
Table 21. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Total Revenue (USD Million) (2017-2018)
Table 22. United Therapeutic Corporation SWOT Analysis
Table 23. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Product and Services
Table 24. United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 26. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Major Business
Table 27. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Total Revenue (USD Million) (2017-2018)
Table 28. Eli Lilly and Company SWOT Analysis
Table 29. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Product and Services
Table 30. Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. Teva Pharmaceuticals Inc Basic Information, Manufacturing Base and Competitors
Table 32. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Major Business
Table 33. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Total Revenue (USD Million) (2017-2018)
Table 34. Teva Pharmaceuticals Inc SWOT Analysis
Table 35. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Product and Services
Table 36. Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Pfizer Inc.Actelion Inc Basic Information, Manufacturing Base and Competitors
Table 38. Pfizer Inc.Actelion Inc Pulmonary Arterial Hypertension Treatment Major Business
Table 39. Pfizer Inc.Actelion Inc Pulmonary Arterial Hypertension Treatment Total Revenue (USD Million) (2017-2018)
Table 40. Pfizer Inc.Actelion Inc SWOT Analysis
Table 41. Pfizer Inc.Actelion Inc Pulmonary Arterial Hypertension Treatment Product and Services
Table 42. Pfizer Inc.Actelion Inc Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Gilead Sciences, Inc Basic Information, Manufacturing Base and Competitors
Table 44. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Major Business
Table 45. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Total Revenue (USD Million) (2017-2018)
Table 46. Gilead Sciences, Inc SWOT Analysis
Table 47. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Product and Services
Table 48. Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 49. SteadyMed Ltd Basic Information, Manufacturing Base and Competitors
Table 50. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Major Business
Table 51. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Total Revenue (USD Million) (2017-2018)
Table 52. SteadyMed Ltd SWOT Analysis
Table 53. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Product and Services
Table 54. SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 55. Global Pulmonary Arterial Hypertension Treatment Sales by Manufacturer (2018-2019) (K MT)
Table 56. Global Pulmonary Arterial Hypertension Treatment Revenue by Manufacturer (2018-2019) (USD Million)
Table 57. Global Pulmonary Arterial Hypertension Treatment Sales by Regions (2015-2020) (K MT)
Table 58. Global Pulmonary Arterial Hypertension Treatment Sales Market Share by Regions (2015-2020)
Table 59. Global Pulmonary Arterial Hypertension Treatment Revenue by Regions (2015-2020) (USD Million)
Table 60. North America Pulmonary Arterial Hypertension Treatment Sales by Countries (2015-2020) (K MT)
Table 61. North America Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries (2015-2020)
Table 62. North America Pulmonary Arterial Hypertension Treatment Revenue by Countries (2015-2020) (USD Million)
Table 63. North America Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries (2015-2020)
Table 64. Europe Pulmonary Arterial Hypertension Treatment Sales by Countries (2015-2020) (K MT)
Table 65. Europe Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries (2015-2020)
Table 66. Europe Pulmonary Arterial Hypertension Treatment Revenue by Countries (2015-2020) (USD Million)
Table 67. Asia-Pacific Pulmonary Arterial Hypertension Treatment Sales by Regions (2015-2020) (K MT)
Table 68. Asia-Pacific Pulmonary Arterial Hypertension Treatment Sales Market Share by Regions (2015-2020)
Table 69. Asia-Pacific Pulmonary Arterial Hypertension Treatment Revenue by Regions (2015-2020) (USD Million)
Table 70. South America Pulmonary Arterial Hypertension Treatment Sales by Countries (2015-2020) (K MT)
Table 71. South America Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries (2015-2020)
Table 72. South America Pulmonary Arterial Hypertension Treatment Revenue by Countries (2015-2020) (USD Million)
Table 73. South America Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries (2015-2020)
Table 74. Middle East & Africa Pulmonary Arterial Hypertension Treatment Sales by Countries (2015-2020) (K MT)
Table 75. Middle East & Africa Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries (2015-2020)
Table 76. Middle East & Africa Pulmonary Arterial Hypertension Treatment Revenue by Countries (2015-2020) (USD Million)
Table 77. Middle East & Africa Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries (2015-2020)
Table 78. Global Pulmonary Arterial Hypertension Treatment Sales by Type (2015-2020) (K MT)
Table 79. Global Pulmonary Arterial Hypertension Treatment Sales Share by Type (2015-2020)
Table 80. Global Pulmonary Arterial Hypertension Treatment Revenue by Type (2015-2020) (USD Million)
Table 81. Global Pulmonary Arterial Hypertension Treatment Revenue Share by Type (2015-2020)
Table 82. Global Pulmonary Arterial Hypertension Treatment Sales by Application (2015-2020) (K MT)
Table 83. Global Pulmonary Arterial Hypertension Treatment Sales Share by Application (2015-2020)
Table 84. Global Pulmonary Arterial Hypertension Treatment Sales Forecast by Regions (2021-2025) (K MT)
Table 85. Global Pulmonary Arterial Hypertension Treatment Market Share Forecast by Regions (2021-2025)
Table 86. Global Pulmonary Arterial Hypertension Treatment Sales Forecast by Type (2021-2025) (K MT)
Table 87. Global Pulmonary Arterial Hypertension Treatment Market Share Forecast by Type (2021-2025)
Table 88. Global Pulmonary Arterial Hypertension Treatment Sales Forecast by Application (2021-2025)
Table 89. Global Pulmonary Arterial Hypertension Treatment Market Share Forecast by Application (2021-2025)
Table 90. Direct Channel Pros & Cons
Table 91. Indirect Channel Pros & Cons
Table 92. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Pulmonary Arterial Hypertension Treatment Picture
Figure 2. Global Sales Market Share of Pulmonary Arterial Hypertension Treatment by Type in 2019
Figure 3. Vasodilators Picture
Figure 4. Phosphodiesterase 5 (PDE 5) Inhibitors Picture
Figure 5. Endothelin Receptor Antagonists (ERA) Picture
Figure 6. Soluble Guanylate Cyclase (SGC) Stimulator Picture
Figure 7. Pulmonary Arterial Hypertension Treatment Sales Market Share by Application in 2018
Figure 8. Hospital Pharmacies Picture
Figure 9. Retail Pharmacies Picture
Figure 10. Online Pharmacies Picture
Figure 11. Global Pulmonary Arterial Hypertension Treatment Market Status and Outlook (2015-2025) (USD Million)
Figure 12. United States Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Canada Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Mexico Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Germany Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 16. France Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 17. UK Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Russia Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Italy Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 20. China Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Japan Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Korea Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 23. India Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Southeast Asia Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Australia Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 26. Brazil Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Egypt Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Saudi Arabia Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 29. South Africa Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Turkey Pulmonary Arterial Hypertension Treatment Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Global Pulmonary Arterial Hypertension Treatment Sales Market Share by Manufacturer in 2019
Figure 32. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Manufacturer in 2019
Figure 33. Top 3 Pulmonary Arterial Hypertension Treatment Manufacturer (Revenue) Market Share in 2019
Figure 34. Top 6 Pulmonary Arterial Hypertension Treatment Manufacturer (Revenue) Market Share in 2019
Figure 35. Key Manufacturer Market Share Trend
Figure 36. Global Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 37. Global Pulmonary Arterial Hypertension Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 38. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Regions (2015-2020)
Figure 39. Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Regions in 2018
Figure 40. North America Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
Figure 41. Europe Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
Figure 42. Asia-Pacific Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
Figure 43. South America Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
Figure 44. Middle East & Africa Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020)
Figure 45. North America Pulmonary Arterial Hypertension Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 46. North America Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries (2015-2020)
Figure 47. North America Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries in 2018
Figure 48. North America Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 49. North America Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries in 2018
Figure 50. United States Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 51. Canada Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 52. Mexico Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 53. Europe Pulmonary Arterial Hypertension Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 54. Europe Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries (2015-2020)
Figure 55. Europe Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries in 2019
Figure 56. Germany Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 57. UK Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 58. France Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 59. Russia Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 60. Italy Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 61. Asia-Pacific Pulmonary Arterial Hypertension Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 62. Asia-Pacific Pulmonary Arterial Hypertension Treatment Sales Market Share by Regions 2019
Figure 63. Asia-Pacific Pulmonary Arterial Hypertension Treatment Revenue Market Share by Regions 2019
Figure 64. China Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 65. Japan Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 66. Korea Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 67. India Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 68. Southeast Asia Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 69. South America Pulmonary Arterial Hypertension Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 70. South America Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries in 2019
Figure 71. South America Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries in 2019
Figure 72. Brazil Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 73. Argentina Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 74. Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue and Growth Rate (2015-2020) (USD Million)
Figure 75. Middle East and Africa Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries in 2019
Figure 76. Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries (2015-2020)
Figure 77. Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries in 2019
Figure 78. Saudi Arabia Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 79. Egypt Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 80. Turkey Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 81. South Africa Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2015-2020) (K MT)
Figure 82. Global Pulmonary Arterial Hypertension Treatment Sales and Growth Rate (2021-2025) (K MT)
Figure 83. Global Pulmonary Arterial Hypertension Treatment Revenue and Growth Rate (2021-2025) (USD Million)
Figure 84. North America Sales Pulmonary Arterial Hypertension Treatment Market Forecast (2021-2025) (K MT)
Figure 85. Europe Sales Pulmonary Arterial Hypertension Treatment Market Forecast (2021-2025) (K MT)
Figure 86. Asia-Pacific Sales Pulmonary Arterial Hypertension Treatment Market Forecast (2021-2025) (K MT)
Figure 87. South America Sales Pulmonary Arterial Hypertension Treatment Market Forecast (2021-2025) (K MT)
Figure 88. Middle East & Africa Sales Pulmonary Arterial Hypertension Treatment Market Forecast (2021-2025) (K MT)
Figure 89. Sales Channel: Direct Channel vs Indirect Channel
肺動脈性肺高血圧症（PAH）の世界市場（～2026年） Market Analysis and Insights: Global Pulmonary Arterial Hypertension (PAH) Market The global Pulmonary Arterial Hypertension (PAH) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Pulmonary Arterial Hypertension (PAH) S…- 慢性血栓塞栓性肺高血圧症（CTEPH）の世界市場（～2026年） Chronic thromboembolic pulmonary hypertension is observed to be one of the leading causes of severe pulmonary hypertension. It is a type of clinical condition in which pulmonary vascular resistance increases giving rise to pulmonary hypertension and progressive heart failure. According to World Heal…
- 特発性頭蓋内圧亢進症治療の世界市場（～2026年） Idiopathic intracranial hypertension is characterized by a buildup of the cerebrospinal fluid causing increase in the blood volume in vessels surrounding the brain and increase in brain swelling. The increase in salt intake causes water retention in the body together with fat adding on to the calori…
- 慢性閉塞性肺疾患治療の世界市場（～2026年） Market Analysis and Insights: Global Chronic Obstructive Pulmonary Disease Treatment Market The global Chronic Obstructive Pulmonary Disease Treatment market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Chronic Obstructive…
- 高血圧治療薬の世界市場（～2026年） The standard definition of high blood pressure is determined by the Joint National Committee (JNC) on Detection, Evaluation, and Diagnosis of High Blood Pressure. A person is considered to have high blood pressure after three to six elevated blood pressure measurements over several months. These def…